


## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1863332/publications.pdf Version: 2024-02-01



STAN

#	Article	IF	CITATIONS
1	Adjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinoma. Gastroenterology, 2015, 148, 1383-1391.e6.	0.6	371
2	A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016. Clinical and Molecular Hepatology, 2016, 22, 7-17.	4.5	232
3	An endoscope with integrated transparent bioelectronics and theranostic nanoparticles for colon cancer treatment. Nature Communications, 2015, 6, 10059.	5.8	159
4	Long-term Prognosis of Combined Hepatocellular and Cholangiocarcinoma After Curative Resection Comparison With Hepatocellular Carcinoma and Cholangiocarcinoma. Journal of Clinical Gastroenterology, 2011, 45, 69-75.	1.1	130
5	Integrative analysis of genomic and epigenomic regulation of the transcriptome in liver cancer. Nature Communications, 2017, 8, 839.	5.8	107
6	Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients. Journal of Hepatology, 2019, 70, 1093-1102.	1.8	107
7	A genome-wide association study identified new variants associated with the risk of chronic hepatitis B. Human Molecular Genetics, 2013, 22, 4233-4238.	1.4	105
8	Serum Tumor Markers Provide Refined Prognostication in Selecting Liver Transplantation Candidate for Hepatocellular Carcinoma Patients Beyond the Milan Criteria. Annals of Surgery, 2016, 263, 842-850.	2.1	105
9	Assessment of hepatic steatosis by using attenuation imaging: a quantitative, easy-to-perform ultrasound technique. European Radiology, 2019, 29, 6499-6507.	2.3	104
10	Real-time US-CT/MR fusion imaging for percutaneous radiofrequency ablation of hepatocellular carcinoma. Journal of Hepatology, 2017, 66, 347-354.	1.8	103
11	Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma. Journal of Hepatology, 2019, 70, 449-457.	1.8	102
12	Small Single-Nodule Hepatocellular Carcinoma: Comparison of Transarterial Chemoembolization, Radiofrequency Ablation, and Hepatic Resection by Using Inverse Probability Weighting. Radiology, 2014, 271, 909-918.	3.6	97
13	Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2018, 67, 1305-1315.	2.0	93
14	Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment. Hepatology, 2017, 66, 1556-1569.	3.6	92
15	High liver fibrosis index FIBâ€4 is highly predictive of hepatocellular carcinoma in chronic hepatitis B carriers. Hepatology, 2015, 61, 1261-1268.	3.6	90
16	Carnitine palmitoyltransferase gene upregulation by linoleic acid induces CD4+ T cell apoptosis promoting HCC development. Cell Death and Disease, 2018, 9, 620.	2.7	90
17	Accuracy of Two-Dimensional Shear Wave Elastography and Attenuation Imaging for Evaluation of Patients With Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology, 2021, 19, 797-805.e7.	2.4	86
18	Visceral Obesity Predicts Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Medicine (United States), 2015, 94, e2159.	0.4	85

#	Article	IF	CITATIONS
19	Spontaneous fungal peritonitis: a severe complication in patients with advanced liver cirrhosis. European Journal of Clinical Microbiology and Infectious Diseases, 2014, 33, 259-264.	1.3	78
20	Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy. Alimentary Pharmacology and Therapeutics, 2017, 46, 845-855.	1.9	73
21	Non-hypervascular hepatobiliary phase hypointense nodules on gadoxetic acid-enhanced MRI: Risk of HCC recurrence after radiofrequency ablation. Journal of Hepatology, 2015, 62, 1122-1130.	1.8	70
22	Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up. Cancer Immunology, Immunotherapy, 2019, 68, 23-32.	2.0	62
23	Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer. , 2017, 5, 93.		56
24	<scp>CLIF</scp> â€ <scp>SOFA</scp> scoring system accurately predicts shortâ€ŧerm mortality in acutely decompensated patients with alcoholic cirrhosis: a retrospective analysis. Liver International, 2015, 35, 46-57.	1.9	55
25	High titers of antiâ€HBs prevent rituximabâ€related viral reactivation in resolved hepatitis B patient with nonâ€Hodgkin's lymphoma. Journal of Medical Virology, 2016, 88, 1010-1017.	2.5	50
26	Hepatitis B viral load affects prognosis of hepatocellular carcinoma. World Journal of Gastroenterology, 2014, 20, 12039.	1.4	50
27	Hypoxia and retinoic acid-inducible NDRG1 expression is responsible for doxorubicin and retinoic acid resistance in hepatocellular carcinoma cells. Cancer Letters, 2010, 298, 9-15.	3.2	49
28	Low-molecular-weight heparin treatment for portal vein thrombosis in liver cirrhosis: Efficacy and the risk of hemorrhagic complications. Thrombosis Research, 2018, 163, 71-76.	0.8	47
29	Steatohepatitis Impairs T-cell–Directed Immunotherapies Against Liver Tumors in Mice. Gastroenterology, 2021, 160, 331-345.e6.	0.6	46
30	Association of Metabolic Risk Factors With Risks of Cancer and All ause Mortality in Patients With Chronic Hepatitis B. Hepatology, 2021, 73, 2266-2277.	3.6	45
31	Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma. Investigational New Drugs, 2019, 37, 567-572.	1.2	44
32	Does 18F-FDG Positron Emission Tomography-Computed Tomography Have a Role in Initial Staging of Hepatocellular Carcinoma?. PLoS ONE, 2014, 9, e105679.	1.1	43
33	Clinical Correlates of Mass Effect in Autosomal Dominant Polycystic Kidney Disease. PLoS ONE, 2015, 10, e0144526.	1.1	43
34	A Comparison of Biannual Two-Phase Low-Dose Liver CT and US for HCC Surveillance in a Group at High Risk of HCC Development. Liver Cancer, 2020, 9, 503-517.	4.2	40
35	Enhancement of hexokinase II inhibitor-induced apoptosis in hepatocellular carcinoma cells via augmenting ER stress and anti-angiogenesis by protein disulfide isomerase inhibition. Journal of Bioenergetics and Biomembranes, 2012, 44, 101-115.	1.0	39
36	Modified AS1411 Aptamer Suppresses Hepatocellular Carcinoma by Up-Regulating Galectin-14. PLoS ONE, 2016, 11, e0160822.	1.1	38

#	Article	IF	CITATIONS
37	Tauroursodeoxycholic Acid Attenuates Progression of Steatohepatitis in Mice Fed a Methionine–Choline-Deficient Diet. Digestive Diseases and Sciences, 2014, 59, 1461-1474.	1.1	37
38	Effective treatment strategies other than sorafenib for the patients with advanced hepatocellular carcinoma invading portal vein. World Journal of Hepatology, 2015, 7, 1553.	0.8	37
39	Serum fibronectin distinguishes the early stages of hepatocellular carcinoma. Scientific Reports, 2017, 7, 9449.	1.6	37
40	Fucoidan protects hepatocytes from apoptosis and inhibits invasion of hepatocellular carcinoma by up-regulating p42/44 MAPK-dependent NDRG-1/CAP43. Acta Pharmaceutica Sinica B, 2015, 5, 544-553.	5.7	36
41	Clinical Assay for AFP-L3 by Using Multiple Reaction Monitoring–Mass Spectrometry for Diagnosing Hepatocellular Carcinoma. Clinical Chemistry, 2018, 64, 1230-1238.	1.5	36
42	Inhibition of hypoxia-inducible carbonic anhydrase-IX enhances hexokinase II inhibitor-induced hepatocellular carcinoma cell apoptosis. Acta Pharmacologica Sinica, 2011, 32, 912-920.	2.8	35
43	Protein disulfide isomerase inhibition synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma. Hepatology, 2017, 66, 855-868.	3.6	35
44	Association of the Frequency and Quantity of Alcohol Consumption With Gastrointestinal Cancer. JAMA Network Open, 2021, 4, e2120382.	2.8	35
45	Balloon-Occluded Retrograde Transvenous Obliteration versus Transjugular Intrahepatic Portosystemic Shunt for the Management of Gastric Variceal Bleeding. Gut and Liver, 2018, 12, 704-713.	1.4	34
46	Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigen–Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective Study. Journal of Infectious Diseases, 2017, 216, 1407-1414.	1.9	33
47	Survival Analysis of Single Large (>5 cm) Hepatocellular Carcinoma Patients: BCLC A versus B. PLoS ONE, 2016, 11, e0165722.	1.1	33
48	Inhibition of PI3K/Akt signaling suppresses epithelial-to-mesenchymal transition in hepatocellular carcinoma through the Snail/GSK-3/beta-catenin pathway. Clinical and Molecular Hepatology, 2020, 26, 529-539.	4.5	33
49	Survival of infiltrative hepatocellular carcinoma patients with preserved hepatic function after treatment with transarterial chemoembolization. Journal of Cancer Research and Clinical Oncology, 2013, 139, 635-643.	1.2	32
50	Efficacy of Entecavir-Tenofovir Combination Therapy for Chronic Hepatitis B Patients with Multidrug-Resistant Strains. Antimicrobial Agents and Chemotherapy, 2014, 58, 6710-6716.	1.4	32
51	Comparison of Transarterial Chemoembolization and Hepatic Resection for Large Solitary Hepatocellular Carcinoma: A Propensity Score Analysis. Journal of Vascular and Interventional Radiology, 2015, 26, 651-659.	0.2	32
52	Hexokinase-II Inhibition Synergistically Augments the Anti-tumor Efficacy of Sorafenib in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2019, 20, 1292.	1.8	32
53	Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment. Clinical and Molecular Hepatology, 2020, 26, 328-339.	4.5	32
54	Risk Factors, Clinical Features, and Prognosis of the Hepatocellular Carcinoma with Peritoneal Metastasis. Digestive Diseases and Sciences, 2012, 57, 813-819.	1.1	31

#	Article	IF	CITATIONS
55	Transarterial chemoembolization of hepatocellular carcinoma with segmental portal vein tumour thrombus. European Radiology, 2017, 27, 1448-1458.	2.3	31
56	Development of Biomarkers for Screening Hepatocellular Carcinoma Using Global Data Mining and Multiple Reaction Monitoring. PLoS ONE, 2013, 8, e63468.	1.1	30
57	Fucoidan-induced ID-1 suppression inhibits the in vitro and in vivo invasion of hepatocellular carcinoma cells. Biomedicine and Pharmacotherapy, 2016, 83, 607-616.	2.5	30
58	Hepatocellular Carcinoma: High Hepatitis B Viral Load and Mortality in Patients Treated with Transarterial Chemoembolization. Radiology, 2013, 267, 638-647.	3.6	28
59	Serum Insulin-like Growth Factor-I Level Is an Independent Predictor of Recurrence and Survival in Early Hepatocellular Carcinoma: A Prospective Cohort Study. Clinical Cancer Research, 2013, 19, 4218-4227.	3.2	28
60	Prior Exposure to Lamivudine Increases Entecavir Resistance Risk in Chronic Hepatitis B Patients without Detectable Lamivudine Resistance. Antimicrobial Agents and Chemotherapy, 2014, 58, 1730-1737.	1.4	28
61	Hypoxia-inducible adrenomedullin accelerates hepatocellular carcinoma cell growth. Cancer Letters, 2008, 271, 314-322.	3.2	27
62	Polymorphisms nearInterleukin 28BGene Are Not Associated with Hepatitis B Virus Clearance, Hepatitis B e Antigen Clearance and Hepatocellular Carcinoma Occurrence. Intervirology, 2013, 56, 84-90.	1.2	27
63	Targeted Proteomics Predicts a Sustained Complete-Response after Transarterial Chemoembolization and Clinical Outcomes in Patients with Hepatocellular Carcinoma: A Prospective Cohort Study. Journal of Proteome Research, 2017, 16, 1239-1248.	1.8	27
64	Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib. Clinical Cancer Research, 2021, 27, 713-718.	3.2	27
65	Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis. Hepatology, 2022, 76, 492-501.	3.6	26
66	Prediction of Response to Sorafenib in Hepatocellular Carcinoma: A Putative Marker Panel by Multiple Reaction Monitoring-Mass Spectrometry (MRM-MS). Molecular and Cellular Proteomics, 2017, 16, 1312-1323.	2.5	25
67	Telbivudine protects renal function in patients with chronic hepatitis <scp>B</scp> infection in conjunction with adefovirâ€based combination therapy. Journal of Viral Hepatitis, 2014, 21, 873-881.	1.0	24
68	Efficacy of antiviral prophylaxis in <scp>HB</scp> sAgâ€negative, antiâ€ <scp>HB</scp> c positive patients undergoing hematopoietic stem cell transplantation. Liver International, 2015, 35, 2530-2536.	1.9	24
69	17β-estradiol exerts anticancer effects in anoikis-resistant hepatocellular carcinoma cell lines by targeting IL-6/STAT3 signaling. Biochemical and Biophysical Research Communications, 2016, 473, 1247-1254.	1.0	24
70	Prognostic Role of Liver Stiffness Measurements Using Magnetic Resonance Elastography in Patients with Compensated Chronic Liver Disease. European Radiology, 2018, 28, 3513-3521.	2.3	24
71	Adjuvant cytokine-induced killer cell immunotherapy for hepatocellular carcinoma: a propensity score-matched analysis of real-world data. BMC Cancer, 2019, 19, 523.	1.1	24
72	Additional fibrate treatment in UDCAâ€refractory PBC patients. Liver International, 2019, 39, 1776-1785.	1.9	24

#	Article	IF	CITATIONS
73	Single-agent Capecitabine in Patients with Metastatic Colorectal Cancer Refractory to 5-Fluorouracil/Leucovorin Chemotherapy. Japanese Journal of Clinical Oncology, 2004, 34, 400-404.	0.6	23
74	Liver Stiffness Measured by Two-Dimensional Shear-Wave Elastography: Prognostic Value after Radiofrequency Ablation for Hepatocellular Carcinoma. Liver Cancer, 2018, 7, 65-75.	4.2	23
75	Entecavir and tenofovir reduce hepatitis B virusâ€related hepatocellular carcinoma recurrence more effectively than other antivirals. Journal of Viral Hepatitis, 2018, 25, 707-717.	1.0	23
76	Risk of Liver Cirrhosis and Hepatocellular Carcinoma after Fontan Operation: A Need for Surveillance. Cancers, 2020, 12, 1805.	1.7	23
77	Liver enzyme variability and risk of heart disease and mortality: A nationwide populationâ€based study. Liver International, 2020, 40, 1292-1302.	1.9	23
78	Association of Polymorphism in Pri-microRNAs-371-372-373 with the Occurrence of Hepatocellular Carcinoma in Hepatitis B Virus Infected Patients. PLoS ONE, 2012, 7, e41983.	1.1	23
79	Hypoxia Enhances Tumor-Stroma Crosstalk that Drives the Progression of Hepatocellular Carcinoma. Digestive Diseases and Sciences, 2016, 61, 2568-2577.	1.1	22
80	Intensity of surveillance for hepatocellular carcinoma determines survival in patients at risk in a hepatitis Bâ€endemic area. Alimentary Pharmacology and Therapeutics, 2018, 47, 1490-1501.	1.9	22
81	Association of <i><scp>VARS</scp>2â€<scp>SFTA</scp>2</i> polymorphisms with the risk of chronic hepatitis B in a Korean population. Liver International, 2015, 35, 1934-1940.	1.9	21
82	Efficacy of Sorafenib for the Treatment of Post-Transplant Hepatocellular Carcinoma Recurrence. Journal of Korean Medical Science, 2018, 33, e283.	1.1	21
83	Nonalcoholic fatty liver disease is a negative risk factor for prostate cancer recurrence. Endocrine-Related Cancer, 2014, 21, 343-353.	1.6	20
84	High-sensitivity C-reactive Protein Level is an Independent Predictor of Poor Prognosis in Cirrhotic Patients With Spontaneous Bacterial Peritonitis. Journal of Clinical Gastroenterology, 2014, 48, 444-449.	1.1	20
85	Tenofovir Monotherapy versus Tenofovir plus Lamivudine or Telbivudine Combination Therapy in Treatment of Lamivudine-Resistant Chronic Hepatitis B. Antimicrobial Agents and Chemotherapy, 2015, 59, 972-978.	1.4	20
86	Radiologic Nonalcoholic Fatty Liver Disease Increases the Risk of Hepatocellular Carcinoma in Patients With Suppressed Chronic Hepatitis B. Journal of Clinical Gastroenterology, 2020, 54, 633-641.	1.1	20
87	Multiparametric US for Identifying Patients with High-Risk NASH: A Derivation and Validation Study. Radiology, 2021, 301, 625-634.	3.6	20
88	Noninvasive fibrosis indices predict intrahepatic distant recurrence of hepatitis Bâ€related hepatocellular carcinoma following radiofrequency ablation. Liver International, 2013, 33, 884-893.	1.9	19
89	Prevalence of upper gastrointestinal bleeding risk factors among the general population and osteoarthritis patients. World Journal of Gastroenterology, 2016, 22, 10643.	1.4	19
90	TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials. British Journal of Cancer, 2016, 115, 1201-1205.	2.9	19

#	Article	IF	CITATIONS
91	Nonalcoholic fatty liver disease increases the risk of diabetes in young adults: A nationwide population-based study in Korea. Metabolism: Clinical and Experimental, 2021, 123, 154866.	1.5	19
92	Switching Monopolar No-Touch Radiofrequency Ablation Using Octopus Electrodes for Small Hepatocellular Carcinoma: A Randomized Clinical Trial. Liver Cancer, 2021, 10, 72-81.	4.2	19
93	STAT3 & amp; Cytochrome P450 2C9: A novel signaling pathway in liver cancer stem cells. Biomedicine and Pharmacotherapy, 2012, 66, 612-616.	2.5	18
94	Spontaneous Evolution in Bilirubin Levels Predicts Liver-Related Mortality in Patients with Alcoholic Hepatitis. PLoS ONE, 2014, 9, e100870.	1.1	18
95	3-bromopyruvate and buthionine sulfoximine effectively kill anoikis-resistant hepatocellular carcinoma cells. PLoS ONE, 2017, 12, e0174271.	1.1	18
96	Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study. BMC Cancer, 2018, 18, 307.	1.1	18
97	Comparison of overall survival between antiviralâ€induced viral suppression and inactive phase chronic hepatitis B patients. Journal of Viral Hepatitis, 2018, 25, 1161-1171.	1.0	18
98	No-Touch vs. Conventional Radiofrequency Ablation Using Twin Internally Cooled Wet Electrodes for Small Hepatocellular Carcinomas: A Randomized Prospective Comparative Study. Korean Journal of Radiology, 2021, 22, 1974.	1.5	18
99	Ursodeoxycholic acid-induced inhibition of DLC1 protein degradation leads to suppression of hepatocellular carcinoma cell growth. Oncology Reports, 2011, 25, 1739-46.	1.2	17
100	Association of a micro <scp>RNA</scp> â€323b polymorphism with the persistence of hepatitis <scp>B</scp> virus infection by the enhancement of viral replication. Journal of Viral Hepatitis, 2014, 21, 853-859.	1.0	17
101	Role of C-Arm CT in Identifying Caudate Arteries Supplying Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2014, 25, 1380-1388.	0.2	17
102	Non-hypervascular hepatobiliary phase hypointense nodules on gadoxetic acid-enhanced MR can help determine the treatment method for HCC. European Radiology, 2019, 29, 3122-3131.	2.3	17
103	A differential risk assessment and decision model for Transarterial chemoembolization in hepatocellular carcinoma based on hepatic function. BMC Cancer, 2020, 20, 504.	1.1	17
104	Comparison of the Effects of Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma between Patients with and without Extrahepatic Metastases. PLoS ONE, 2014, 9, e113926.	1.1	17
105	Child-Pugh B or C Cirrhosis Increases the Risk for Bleeding Following Colonoscopic Polypectomy. Gut and Liver, 2020, 14, 755-764.	1.4	17
106	Relationship between polymorphisms near the <i><scp>IL</scp>28B</i> gene and spontaneous <scp>HB</scp> sAg seroclearance: a systematic review and metaâ€analysis. Journal of Viral Hepatitis, 2014, 21, 163-170.	1.0	16
107	Synergistic anti-tumor efficacy of doxorubicin and flavopiridol in an in vivo hepatocellular carcinoma model. Journal of Cancer Research and Clinical Oncology, 2015, 141, 2037-2045.	1.2	16
108	Hepatoprotective effect of vitamin C on lithocholic acid-induced cholestatic liver injury in Gulo(â^'/â^') mice. European Journal of Pharmacology, 2015, 762, 247-255.	1.7	16

#	Article	IF	CITATIONS
109	Prognostic Value of Biochemical Response Models for Primary Biliary Cholangitis and the Additional Role of the Neutrophil-to-Lymphocyte Ratio. Gut and Liver, 2018, 12, 714-721.	1.4	16
110	A novel prognostic factor for hepatocellular carcinoma: protein disulfide isomerase. Korean Journal of Internal Medicine, 2014, 29, 580.	0.7	16
111	Guggulsterone attenuates activation and survival of hepatic stellate cell by inhibiting nuclear factor kappa B activation and inducing apoptosis. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 1859-1868.	1.4	15
112	Forns index predicts recurrence and death in patients with hepatitis Bâ€related hepatocellular carcinoma after curative resection. Liver International, 2015, 35, 1992-2000.	1.9	15
113	Tenofovir-associated nephrotoxicity in patients with chronic hepatitis B: two cases. Clinical and Molecular Hepatology, 2016, 22, 286-291.	4.5	15
114	Bleeding complications in critically ill patients with liver cirrhosis. Korean Journal of Internal Medicine, 2016, 31, 288-295.	0.7	15
115	Sub-classification of Advanced-Stage Hepatocellular Carcinoma: A Cohort Study Including 612 Patients Treated with Sorafenib. Cancer Research and Treatment, 2018, 50, 366-373.	1.3	15
116	Young adults with nonalcoholic fatty liver disease, defined using the fatty liver index, can be at increased risk of myocardial infarction or stroke. Diabetes, Obesity and Metabolism, 2022, 24, 465-472.	2.2	15
117	Anti-apoptotic N-cadherin signaling and its prognostic implication in human hepatocellular carcinomas. Oncology Reports, 2006, 15, 1117-23.	1.2	15
118	Paper Alert. European Journal of Gastroenterology and Hepatology, 2019, 31, 1295-1298.	0.8	14
119	Switching Monopolar Radiofrequency Ablation Using a Separable Cluster Electrode in Patients with Hepatocellular Carcinoma: A Prospective Study. PLoS ONE, 2016, 11, e0161980.	1.1	14
120	Timing of upper gastrointestinal endoscopy does not influence short-term outcomes in patients with acute variceal bleeding. World Journal of Gastroenterology, 2018, 24, 5025-5033.	1.4	14
121	Predictors of HBsAg Seroclearance in HBeAg-Negative Chronic Hepatitis B Patients. Digestion, 2011, 84, 23-28.	1.2	13
122	Efficacy of Adefovir-Based Combination Therapy for Patients with Lamivudine- and Entecavir-Resistant Chronic Hepatitis B Virus Infection. Antimicrobial Agents and Chemotherapy, 2013, 57, 6325-6332.	1.4	13
123	Measurement of Glycosylated Alpha-Fetoprotein Improves Diagnostic Power over the Native Form in Hepatocellular Carcinoma. PLoS ONE, 2014, 9, e110366.	1.1	13
124	Percutaneous ethanol injection therapy is comparable to radiofrequency ablation in hepatocellular carcinoma smaller than 1.5 cm. Medicine (United States), 2016, 95, e4551.	0.4	13
125	Synergistic effect of cytokine-induced killer cell with valproate inhibits growth of hepatocellular carcinoma cell in a mouse model. Cancer Biology and Therapy, 2017, 18, 67-75.	1.5	13
126	Identification of novel <i><scp>OCT</scp>4</i> genetic variant associated with the risk of chronic hepatitis B in a Korean population. Liver International, 2017, 37, 354-361.	1.9	13

#	Article	IF	CITATIONS
127	Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naÃ⁻ve patients. Clinical and Molecular Hepatology, 2017, 23, 66-73.	4.5	13
128	Initial Alpha-Fetoprotein Response Predicts Prognosis in Hepatitis B-related Solitary HCC Patients After Radiofrequency Ablation. Journal of Clinical Gastroenterology, 2018, 52, e18-e26.	1.1	13
129	Identification of additional EHMT2 variant associated with the risk of chronic hepatitis B by GWAS follow-up study. Genes and Immunity, 2019, 20, 1-9.	2.2	13
130	Prognostic impact of concurrent nonalcoholic fatty liver disease in patients with chronic hepatitis Bâ€related hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1960-1968.	1.4	13
131	Sodium taurocholate cotransporting polypeptide mediates dual actions of deoxycholic acid in human hepatocellular carcinoma cells: enhanced apoptosis versus growth stimulation. Journal of Cancer Research and Clinical Oncology, 2014, 140, 133-144.	1.2	12
132	The Safety and Clinical Outcomes of Chemoembolization in Child-Pugh Class C Patients with Hepatocellular Carcinomas. Korean Journal of Radiology, 2015, 16, 1283.	1.5	12
133	Cone Beam CT–Guided Chemoembolization of Probable Hepatocellular Carcinomas Smaller than 1 cm in Patients at High Risk of Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2017, 28, 795-803.e1.	0.2	12
134	Percutaneous Dual-Switching Monopolar Radiofrequency Ablation Using a Separable Clustered Electrode: A Preliminary Study. Korean Journal of Radiology, 2017, 18, 799.	1.5	12
135	Synergistic effect of ursodeoxycholic acid on the antitumor activity of sorafenib in hepatocellular carcinoma cells via modulation of STAT3 and ERK. International Journal of Molecular Medicine, 2018, 42, 2551-2559.	1.8	12
136	The Clinicopathological and Prognostic Significance of Nrf2 and Keap1 Expression in Hepatocellular Carcinoma. Cancers, 2020, 12, 2128.	1.7	12
137	Entecavir Plus Pegylated Interferon and Sequential Hepatitis B Virus Vaccination Increases Hepatitis B Surface Antigen Seroclearance: A Randomized Controlled Proof-of-Concept Study. Clinical Infectious Diseases, 2020, 73, e3308-e3316.	2.9	12
138	Two-Dimensional-Shear Wave Elastography with a Propagation Map: Prospective Evaluation of Liver Fibrosis Using Histopathology as the Reference Standard. Korean Journal of Radiology, 2020, 21, 1317.	1.5	12
139	Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea. Clinical and Molecular Hepatology, 2015, 21, 358.	4.5	12
140	Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1565-1577.	1.8	12
141	Retinoic acid and its binding protein modulate apoptotic signals in hypoxic hepatocellular carcinoma cells. Cancer Letters, 2010, 295, 229-235.	3.2	11
142	<i>TGFBR3</i> Polymorphisms and Its Haplotypes Associated with Chronic Hepatitis B Virus Infection and Age of Hepatocellular Carcinoma Occurrence. Digestive Diseases, 2011, 29, 278-283.	0.8	11
143	Validation of a Modified Child-Turcotte-Pugh Classification System Utilizing Insulin-Like Growth Factor-1 for Patients with Hepatocellular Carcinoma in an HBV Endemic Area. PLoS ONE, 2017, 12, e0170394.	1.1	11
144	Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in <scp>HB</scp> eAgâ€positive high viral load chronic hepatitis B. Journal of Viral Hepatitis, 2018, 25, 552-560.	1.0	11

#	Article	IF	CITATIONS
145	Comparison of Models for Tumor Recurrence after Liver Transplantation for the Patients with Hepatocellular Carcinoma: A Multicenter Long-Term Follow-Up Study. Cancers, 2019, 11, 1295.	1.7	11
146	Glucose Variability and Risk of Hepatocellular Carcinoma in Patients with Diabetes: A Nationwide Population-Based Study. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 974-981.	1.1	11
147	Serum Insulin-Like Growth Factor-1 Predicts Disease Progression and Survival in Patients with Hepatocellular Carcinoma Who Undergo Transarterial Chemoembolization. PLoS ONE, 2014, 9, e90862.	1.1	11
148	Validation of P2/MS and Other Noninvasive Fibrosis Scoring Systems in the Korean Population with Nonalcoholic Fatty Liver Disease. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2011, 57, 19.	0.2	10
149	Topographical Impact of Hepatitis B-related Hepatocellular Carcinoma on Local Recurrence After Radiofrequency Ablation. Journal of Clinical Gastroenterology, 2014, 48, 66-72.	1.1	10
150	Prognostic stratification and nomogram for survival prediction in hepatocellular carcinoma patients treated with radiotherapy for lymph node metastasis. British Journal of Radiology, 2016, 89, 20160383.	1.0	10
151	Anakinra Protects Against Serum Deprivation-Induced Inflammation and Functional Derangement in Islets Isolated From Nonhuman Primates. American Journal of Transplantation, 2017, 17, 365-376.	2.6	10
152	Timely diagnosis of pulmonary artery tumor embolism by ultrasoundâ€guided transbronchial needle aspiration. Thoracic Cancer, 2014, 5, 184-187.	0.8	9
153	A quantitative analytical method for PIVKA-II using multiple reaction monitoring-mass spectrometry for early diagnosis of hepatocellular carcinoma. Analytical and Bioanalytical Chemistry, 2017, 409, 2829-2838.	1.9	9
154	Fully validated SRM-MS-based method for absolute quantification of PIVKA-II in human serum: Clinical applications for patients with HCC. Journal of Pharmaceutical and Biomedical Analysis, 2018, 156, 142-146.	1.4	9
155	Hepatitis B virus X protein induces size-selective membrane permeabilization through interaction with cardiolipin. Biochimica Et Biophysica Acta - Biomembranes, 2019, 1861, 729-737.	1.4	9
156	Quantitative Assessment of Fatty Liver using Ultrasound withÂNormalized Local Variance Technique. Ultraschall in Der Medizin, 2021, 42, 599-606.	0.8	9
157	Clinical Characteristics of Long-Term Survivors After Sorafenib Treatment for Unresectable Hepatocellular Carcinoma: A Korean National Multicenter Retrospective Cohort Study. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 613-623.	1.8	9
158	Comparison of Overall Survival between Surgical Resection and Radiofrequency Ablation for Hepatitis B-Related Hepatocellular Carcinoma. Cancers, 2021, 13, 6009.	1.7	9
159	Oral Medications Enhance Adherence to Surveillance for Hepatocellular Carcinoma and Survival in Chronic Hepatitis B Patients. PLoS ONE, 2017, 12, e0166188.	1.1	8
160	Ultrasound-guided percutaneous portal transplantation of peripheral blood monocytes in patients with liver cirrhosis. Korean Journal of Internal Medicine, 2017, 32, 261-268.	0.7	8
161	Tumor Marker-Based Definition of the Transarterial Chemoembolization-Refractoriness in Intermediate-Stage Hepatocellular Carcinoma: A Multi-Cohort Study. Cancers, 2019, 11, 1721.	1.7	8
162	Epidemiological and Clinical History of Viral Hepatitis in Korea. Infection and Chemotherapy, 2021, 53, 159.	1.0	8

#	Article	IF	CITATIONS
163	Radiofrequency Ablation Using a Separable Clustered Electrode for the Treatment of Hepatocellular Carcinomas: A Randomized Controlled Trial of a Dual-Switching Monopolar Mode Versus a Single-Switching Monopolar Mode. Korean Journal of Radiology, 2021, 22, 179.	1.5	8
164	Comparison of the Efficacy of Entecavir and Tenofovir in Nucleos(T)ide Analogue-Experienced Chronic Hepatitis B Patients. PLoS ONE, 2015, 10, e0130392.	1.1	8
165	Radiofrequency ablation using internally cooled wet electrodes in bipolar mode for the treatment of recurrent hepatocellular carcinoma after locoregional treatment: A randomized prospective comparative study. PLoS ONE, 2020, 15, e0239733.	1.1	8
166	Repeated Intra-Arterial Therapy via the Cystic Artery for Hepatocellular Carcinoma. CardioVascular and Interventional Radiology, 2014, 37, 1283-1291.	0.9	7
167	Differential Effect of HCV Eradication and Fibrosis Grade on Hepatocellular Carcinoma and All-cause Mortality. Scientific Reports, 2018, 8, 13651.	1.6	7
168	Carbonic anhydrase-IX inhibition enhances the efficacy of hexokinase II inhibitor for hepatocellular carcinoma in a murine model. Journal of Bioenergetics and Biomembranes, 2019, 51, 121-129.	1.0	7
169	Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C. Gut and Liver, 2021, 15, 410-419.	1.4	7
170	Comparison of biochemical response during antiviral treatment in patients with chronic hepatitis B infection. Liver International, 2022, 42, 320-329.	1.9	7
171	Prognostic Values of Inflammation-Based Scores and Fibrosis Markers in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. Diagnostics, 2022, 12, 1170.	1.3	7
172	The Efficacy of Adefovir Plus Entecavir Combination Therapy in Patients with Chronic Hepatitis B Refractory to Both Lamivudine and Adefovir. Digestive Diseases and Sciences, 2013, 58, 1363-1370.	1.1	6
173	Reduction of Oxidative Stress Attenuates Lipoapoptosis Exacerbated by Hypoxia in Human Hepatocytes. International Journal of Molecular Sciences, 2015, 16, 3323-3334.	1.8	6
174	Scoring system for risk stratification of viral reactivation during prophylactic antiviral treatment in Korean patients with hepatitis B undergoing anticancer chemotherapy: A multicenter study. Journal of Medical Virology, 2018, 90, 1593-1603.	2.5	6
175	Favorable impact of nonâ€alcoholic fatty liver disease on the cerebral white matter hyperintensity in a neurologically healthy population. European Journal of Neurology, 2019, 26, 1471-1478.	1.7	6
176	Weight fluctuation and risk of hepatocellular carcinoma: a nationwide population-based 8-million-subject study. Hepatology International, 2021, 15, 482-492.	1.9	6
177	Assessment of the Surveillance Interval at 1 Year after Curative Treatment in Hepatocellular Carcinoma: Risk Stratification. Gut and Liver, 2018, 12, 571-582.	1.4	6
178	Nonalcoholic Fatty Liver Disease Is a Precursor of New-Onset Metabolic Syndrome in Metabolically Healthy Young Adults. Journal of Clinical Medicine, 2022, 11, 935.	1.0	6
179	A model to estimate survival in ambulatory patients with hepatocellular carcinoma: Can it predict the natural course of hepatocellular carcinoma?. Digestive and Liver Disease, 2017, 49, 1273-1279.	0.4	5
180	Mesalamineâ€induced B7â€H1 expression on hepatic stellate cells attenuates autoimmune liver injury. Hepatology Research, 2011, 41, 79-86.	1.8	4

#	Article	IF	CITATIONS
181	Simple Scoring System Predicting Genotypic Resistance During Rescue Therapy for Lamivudine-Resistant Chronic Hepatitis B. Journal of Clinical Gastroenterology, 2012, 46, 243-250.	1.1	4
182	Side population in <scp>LX2</scp> cells decreased by transforming growth factorâ€Î². Hepatology Research, 2014, 44, 229-237.	1.8	4
183	JNK signaling in hepatocarcinoma cells is associated with the side population upon treatment with anticancer drugs. Molecular Medicine Reports, 2015, 11, 263-268.	1.1	4
184	Hepatitis B Virus-Related Glomerulonephritis: Not a Predominant Cause of Proteinuria in Korean Patients with Chronic Hepatitis B. Gastroenterology Research and Practice, 2015, 2015, 1-6.	0.7	4
185	Differential sensitivity of hepatocellular carcinoma cells to suppression of hepatocystin transcription under hypoxic conditions. Journal of Bioenergetics and Biomembranes, 2016, 48, 581-590.	1.0	4
186	CKD-5, a novel pan-histone deacetylase inhibitor, synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma. BMC Cancer, 2020, 20, 1001.	1.1	4
187	Systems analysis identifies endothelin 1 axis blockade for enhancing the anti-tumor effect of multikinase inhibitor. Cancer Gene Therapy, 2021, , .	2.2	4
188	Concurrent transarterial radioembolization and combination atezolizumab/ bevacizumab treatment of infiltrative hepatocellular carcinoma with portal vein tumor thrombosis: a case report. Journal of Liver Cancer, 2022, 22, 69-74.	0.3	4
189	Prognosis of surgical hernia repair in cirrhotic patients with refractory ascites. Hernia: the Journal of Hernias and Abdominal Wall Surgery, 2020, 24, 481-488.	0.9	3
190	Direct-Acting Antivirals Improve Treatment Outcomes in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: A Nationwide, Multi-center, Retrospective Cohort Study. Digestive Diseases and Sciences, 2020, 66, 2427-2438.	1.1	3
191	Comparative study on proliferation activity in small hepatocellular carcinoma related to hepatitis virus B and C. World Journal of Gastroenterology, 1997, 3, 236.	1.4	3
192	Deciphering and Reversing Immunosuppressive Cells in the Treatment of Hepatocellular Carcinoma. Journal of Liver Cancer, 2020, 20, 1-16.	0.3	3
193	Regression of liver cirrhosis: Orthodoxy or paradigm shift?. Clinical and Molecular Hepatology, 2015, 21, 22.	4.5	2
194	Validation of P2/MS for reflecting hepatic fibrosis in patients with hepatocellular carcinoma. The Korean Journal of Hepatology, 2010, 16, 389.	1.5	2
195	Long-term Nucleotide Analogue Treatment Has Higher Levels of Renal Toxicities than Does Entecavir in Patients with Chronic Hepatitis B. Gut and Liver, 2020, 14, 225-231.	1.4	2
196	Anticoagulation Treatment with Low Molecular-Weight Heparin for Portal Vein Thrombosis in Liver Cirrhosis: Efficacy and Risk of Hemorrhagic Complications. Blood, 2016, 128, 1435-1435.	0.6	2
197	Lack of association between serum leptin levels and hepatic steatosis, fibrosis or response to antiviral therapy in Korean chronic hepatitis C patients. Hepato-Gastroenterology, 2007, 54, 844-8.	0.5	2
198	Low P2/MS value is an independent risk factor for early recurrence of hepatocellular carcinoma after radiofrequency ablation therapy. Hepato-Gastroenterology, 2011, 58, 147-52.	0.5	2

#	Article	IF	CITATIONS
199	Molecular targeted therapy with transarterial chemoembolization. Gastrointestinal Intervention, 2013, 2, 78-81.	0.1	1
200	A Model for Adaptive Decision Making of "Ablate-and-Wait―Versus Transplantation in Patients With Hepatocellular Carcinoma. Journal of Clinical Gastroenterology, 2018, 52, 655-661.	1.1	1
201	Is Combination Antiviral Therapy Mandatory for Maintenance Therapy in Fully Suppressed Multidrug-Resistant Hepatitis B Patients?. Gastroenterology Research and Practice, 2018, 2018, 1-9.	0.7	1
202	Effectiveness of Transarterial Chemoembolization-First Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 587-598.	1.8	1
203	Proposal of a New Risk Score for Patients Treated with Transarterial Chemoembolization due to Recurrent Hepatocellular Carcinoma after Curative Resection: A Multicenter Study. Gut and Liver, 2020, 14, 477-485.	1.4	1
204	Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria. Oncotarget, 2017, 8, 47555-47564.	0.8	1
205	Tenofovir and Entecavir Have Similar Renal Adverse Events on Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization. Journal of Liver Cancer, 2019, 19, 128-135.	0.3	1
206	Appraisal of a Model to Estimate Survival in Ambulatory Patients with Hepatocellular Carcinoma Classified as Barcelona Clinic Liver Cancer Stage B. Gut and Liver, 2020, 14, 377-386.	1.4	1
207	Disparities in Liver Cancer Surveillance Among People With Disabilities. Journal of Clinical Gastroenterology, 2021, 55, 439-448.	1.1	1
208	Comparison of the efficacies of entecavir 0.5 and 1.0 mg combined with adefovir in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analogue treatments. Journal of Medical Virology, 2015, 87, 999-1007.	2.5	0
209	The association between microRNAâ€323b polymorphism and hepatitis B virus persistent infection – some problems should be addressed. Journal of Viral Hepatitis, 2015, 22, 626-626.	1.0	0
210	Concomitant food intake does not affect the efficacy of entecavir in chronic hepatitis B patients with virological response: a randomized, multicenter, noninferiority trial. Drug Design, Development and Therapy, 2018, Volume 12, 3767-3774.	2.0	0
211	Analysis of significant protein abundance from multiple reaction-monitoring data. BMC Systems Biology, 2018, 12, 123.	3.0	Ο
212	SAT-224-Design and validation of a risk prediction model for hepatocellular carcinoma development after sustained virological response in chronic hepatitis C patients. Journal of Hepatology, 2019, 70, e728.	1.8	0
213	FRI-035-Clinical outcomes associated with additional fibrate treatment in UDCA-refractory PBC patients: A multicenter study. Journal of Hepatology, 2019, 70, e399-e400.	1.8	0
214	The Model to Estimate Survival in Ambulatory Hepatocellular Carcinoma Patients Aids in the Decision for TACE Retreatment. Journal of Clinical Gastroenterology, 2020, 54, 370-377.	1.1	0
215	Direct-acting antivirals improve treatment outcomes in patients with chronic hepatitis C-related hepatocellular carcinoma treated with transarterial chemoembolization: a nationwide, multi-center, retrospective cohort study. Journal of Hepatology, 2020, 73, S612-S613.	1.8	0
216	Comparative effectiveness of nivolumab versus regorafenib for hepatocellular carcinoma patients who experienced sorafenib failure. Journal of Hepatology, 2020, 73, S913-S914.	1.8	0

#	Article	IF	CITATIONS
217	Empirical carbapenem versus third-generation cephalosporin treatment for spontaneous bacterial peritonitis: a multicenter study. Journal of Hepatology, 2020, 73, S769-S770.	1.8	0
218	Comparison of the risk of hepatocellular carcinoma in nucleos(t) ide analogue-naive chronic hepatitis B patients treated with entecavir versus tenofovir : a systematic review and meta-analysis. Journal of Hepatology, 2020, 73, S582-S583.	1.8	0
219	A Case of Acrometastasis in the Right First Metatarsal Bone Caused by a Metastatic Hepatocellular Carcinoma. Korean Journal of Medicine, 2013, 84, 81.	0.1	0
220	Hepatocellular Carcinoma with Segmental Portal Vein Invasion Exhibiting a Complete Response after Transarterial Radioembolization. Journal of Liver Cancer, 2019, 19, 159-164.	0.3	0